The treatment landscape of triple-negative breast cancer

• Published in: Medical oncology (Northwood, London, England) Vol. 41; no. 10; p. 236
• Main Authors: Hu, Yi, Wang, Chen, Liang, Huishi, Li, Jie, Yang, Qiong
• Format: Journal Article
• Language: English
• Published: New York Springer US 29.08.2024; Springer Nature B.V
• Subjects: Androgens; Antibodies; Breast cancer; Cell cycle; Clinical trials; Cytokines; DNA damage; DNA repair; FDA approval; Genes; Growth factors; Hematology; Immunotherapy; Internal Medicine; Medical prognosis; Medical research; Medicine; Medicine & Public Health; Metastasis; Mutation; Oncology; Pathology; Proteins; Review Article; Tumors; Immunotherapy; Personalized treatment; Triple-negative breast cancer
• ISSN: 1559-131X; 1357-0560; 1559-131X
• DOI: 10.1007/s12032-024-02456-9

Triple-negative breast cancer (TNBC) tumors are biologically aggressive breast cancer. On the molecular level, TNBC is a highly heterogeneous disease; more biotechnologies are gradually being used to advance the understanding of TNBC subtypes and help establish more targeted therapies. Multiple TNBC target-related agents are already approved by the Food and Drug Administration for clinical use, including PI3K/AKT/mTOR inhibitors, PRAP inhibitors, and antibody-drug conjugates. Some innovative approaches, like peptide strategies, also promise to treat TNBC. Currently, the interplay between TNBC tumors and their tumor microenvironment provides a promising prospect for improving the efficacy of immunotherapy. In this review, we summarize the prevalent TNBC subtype methodologies, discuss the evolving therapeutic strategies, and propose new therapeutic possibilities based on existing foundational theories, with the attempt to serve as a reference to further advance tailoring treatment of TNBC.